에 대한 최신 뉴스 NuCana (NASDAQ:NCNA) 주식

NuCana

NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.

NuCana PLC

News

Guidance

ELAN

Elanco Animal Health Raises FY25 Revenue Guidance From $4.445B - $4.510B To $4.510B - $4.580B Vs. $4.484B Est.

Earnings

Earnings Beats

Earnings Misses

Cencora Q2 Adj. EPS $4.42 Beats $4.11 Estimate, Sales $75.45B Miss $75.68B Estimate

Perrigo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRGO#NYSE">PRGO</a>) reported quarterly earnings of $0.60 per share which beat the analyst consensus estimate of $0.55 by 9.09 percent. This is a 106.9 percent increase over earnings of $0.29 per share from the same period last year. The company reported quarterly sales of $1.04 billion which missed the analyst consensus estimate of $1.09 billion by 3.92 percent. This is a 3.51 percent decrease over sales of $1.08 billion the same period last year.

PRGO

Perrigo Q1 Adj. EPS $0.60 Beats $0.55 Estimate, Sales $1.04B Miss $1.09B Estimate

MarketAxess Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKTX#NASDAQ">MKTX</a>) reported quarterly earnings of $1.87 per share which beat the analyst consensus estimate of $1.81 by 3.31 percent. This is a 2.6 percent decrease over earnings of $1.92 per share from the same period last year. The company reported quarterly sales of $208.58 million which missed the analyst consensus estimate of $209.72 million by 0.54 percent. This is a 0.83 percent decrease over sales of $210.32 million the same period last year.

MKTX

MarketAxess Holdings Q1 Adj. EPS $1.87 Beats $1.81 Estimate, Sales $208.58M Miss $209.72M Estimate

Bio-Techne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>) reported quarterly earnings of $0.56 per share which beat the analyst consensus estimate of $0.51 by 9.8 percent. This is a 16.67 percent increase over earnings of $0.48 per share from the same period last year. The company reported quarterly sales of $316.18 million which missed the analyst consensus estimate of $317.53 million by 0.43 percent. This is a 4.20 percent increase over sales of $303.43 million the same period last year.

TECH

Bio-Techne Q3 Adj. EPS $0.56 Beats $0.51 Estimate, Sales $316.18M Miss $317.53M Estimate

Elanco Animal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELAN#NYSE">ELAN</a>) reported quarterly earnings of $0.37 per share which beat the analyst consensus estimate of $0.31 by 19.35 percent. This is a 8.82 percent increase over earnings of $0.34 per share from the same period last year. The company reported quarterly sales of $1.19 billion which beat the analyst consensus estimate of $1.17 billion by 2.11 percent. This is a 1.00 percent decrease over sales of $1.21 billion the same period last year.

Elanco Animal Health Q1 Adj. EPS $0.37 Beats $0.31 Estimate, Sales $1.19B Beat $1.17B Estimate

On Tuesday, billionaire investor Bill Ackman suggested that Donald Trump implement a gradual, escalating China tariff strategy to encourage fair trade negotiations and help U.S. companies adjust without triggering sudden economic disruption.
What Happened: Taking to X, formerly Twitter, Ackman laid out a detailed proposal for how Trump could reshape U.S.-China trade relations.
Rather than imposing large tariffs abruptly, Ackman suggests starting with a 20% tariff on Chinese goods and then gradually increasing it:
<ul>
<li>By 0.5% per month over the first year,</li>
<li>By 1% per month in the second year,</li>
<li>And by 1.5% per month in the third year, continuing in this pattern.</li>
</ul>
"To the extent that China modifies its unfair trade practices, the increases could stop and potentially be reversed depending upon the degree of improvement in its trade policies," Ackman explained.
See Also:&nbsp;<a href="https://www.benzinga.com/media/25/05/45216185/bill-gates-says-trumps-climate-rollbacks-may-have-slowed-progress-but-microsoft-co-founder-doesnt-think-thats-a-permanent-thing-as-americas-commitment-to-clean-energy" target="_blank" rel="noreferrer noopener">Bill Gates Says Trump's Climate Rollbacks May Have Slowed Progress, But Microsoft Co-Founder Doesn't Think ‘That's a Permanent Thing'</a>
He added, "This approach would incentivize companies to relocate their supply chains from China while enabling them to continue to operate profitably during the transition."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">What if <a href="https://twitter.com/realDonaldTrump?ref_src=twsrc%5Etfw">@realDonaldTrump</a> were to announce that China tariffs would immediately be reduced to 20% and then escalate thereafter by 0.5% per month for next 12 months, and then by 1% per month for the next 12 months, and then by 1.5% per month for the next 12 months and so on? To…
&mdash; Bill Ackman (@BillAckman) <a href="https://twitter.com/BillAckman/status/1919840513831973363?ref_src=twsrc%5Etfw">May 6, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It's Important: On the same day as Ackman's proposal, the Trump administration revealed that Treasury Secretary Scott Bessent and U.S. Trade Representative Jamieson Greer are set to meet with <a href="https://www.benzinga.com/25/05/45242461/donald-trumps-trade-war-sparks-first-major-us-china-talks-scott-bessent-jamieson-greer-to-meet-chinese-delegation-in-geneva">senior Chinese officials in Geneva</a>, Switzerland, this weekend.
China's Ministry of Commerce released a separate statement warning that if the U.S. were to act contrary to its stated intentions or use the dialogue as a cover for pressure tactics, <a href="https://www.benzinga.com/25/05/45246445/china-warns-us-not-to-use-coercion-and-extortion-tactics-ahead-of-first-major-trade-talks-in-geneva-says-it-will-never-accept-it-if-americans-use-dialogue-as-smokescreen">China would not tolerate</a> such behavior.
A recent poll shows that the trade war has <a href="https://www.benzinga.com/markets/25/05/45185792/young-americans-express-discontent-over-trumps-china-tariffs">negatively affected</a> President Trump's approval ratings among young Americans, who are frustrated by the price increases caused by tariffs.
The Invesco QQQ Trust, Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) has declined 5.65% so far this year, while the SPDR S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) has dropped 4.42%, as ongoing uncertainty surrounding the U.S.-China trade conflict continues to dampen investor confidence.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/25/04/45090992/mark-zuckerberg-warns-of-serious-disadvantage-as-chinas-data-center-blitz-could-let-deepseek-leapfrog-us-ai-labs" target="_blank" rel="noreferrer noopener">Mark Zuckerberg Warns Of ‘Serious Disadvantage' As China's Data-Center Blitz Could Let DeepSeek Leapfrog US AI Labs</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: T. Schneider / Shutterstock.com

Politics

Media

Bill Ackman Proposes Gradual China Tariff Escalation To Push Fair Trade And Avoid Economic Shock: 'This Approach Would Incentivize Companies...'

Valneva (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VALN#NASDAQ">VALN</a>) lowers FY2025 sales outlook from $192.11 million-$202.78 million to $189.29 million-$199.81 million.

VALN

Valneva Lowers FY2025 Sales Guidance from $192.11M-$202.78M to $189.29M-$199.81M

Valneva (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VALN#NASDAQ">VALN</a>) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.20) by 35 percent. This is a 114.61 percent decrease over earnings of $0.89 per share from the same period last year. The company reported quarterly sales of $51.77 million which beat the analyst consensus estimate of $40.20 million by 28.79 percent. This is a 45.54 percent increase over sales of $35.57 million the same period last year.

Valneva Q1 EPS $(0.13) Beats $(0.20) Estimate, Sales $51.77M Beat $40.20M Estimate

LIVN

LivaNova Updates FY2025 Adj EPS Guidance from $3.65-$3.75 to $3.60-$3.70 vs $3.56 Est; Updates FY2025 Sales Guidance from $1.30B-$1.30B to $1.32B-$1.34B On A Reported Basis vs $1.30B Est

Amazon.com Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) autonomous vehicle company Zoox has reportedly recalled over 270 vehicles to rectify a software issue that led to a crash in Las Vegas, Nevada, on April 8, 2025.
What Happened: A Zoox robotaxi, which had no occupants at the time, crashed into a passenger vehicle in Las Vegas. However, no injuries were reported following the accident, Reuters reported on Tuesday.
Following the crash, the company had reportedly halted operations and initiated a safety review as well as developed a software update to rectify the issue, the report suggests.
Zoox says its software "may make an inaccurate prediction when another vehicle slowly approaches perpendicularly and stops. In these scenarios, the Zoox vehicle may not be able to avoid a crash.&#8221;
The AV company also conceded that the issue may occur at speeds greater than 40 miles per hour when a vehicle "incrementally encroaches" from a perpendicular driveway, the report said.
Why It Matters: The recall comes in as the autonomous vehicle sector in the U.S. is steadily gaining pace, with Alphabet Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) Waymo leading the charge, followed by Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) and Zoox.&nbsp;
Waymo <a href="https://www.benzinga.com/markets/equities/25/04/45090602/google-backed-waymo-and-toyota-forge-strategic-partnership-to-bring-autonomous-driving-tech-to-personally-owned-vehicles">recently partnered</a> with Toyota Motor Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TM#NYSE">TM</a>) to collaborate on developing autonomous vehicles, with special focus on personal ownership. Tesla CEO Elon Musk also reaffirmed the company's <a href="https://www.benzinga.com/tech/25/05/45213809/teslas-elon-musk-says-manually-driven-cars-will-be-unusual-in-the-future-shares-updates-on-spacex-neuralink">June Robotaxi launch</a> in Austin.
Elsewhere, Uber Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) recently <a href="https://www.benzinga.com/markets/25/05/45162888/uber-heats-up-robotaxi-battle-against-tesla-waymo-with-may-mobility-deal">announced a partnership</a> with AV company May Mobility to operate thousands of robotaxis on the Uber platform. The company also <a href="https://www.benzinga.com/25/05/45214653/uber-could-win-the-robo-taxi-war-says-expert-analyst-predicts-75-gains-on-ride-hailing-cost-drop">got into an agreement</a> with German automaker Volkswagen AG (OTCPK: VLKAF) to operate VW ID. Buzz robotaxis in the U.S.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img loading="lazy" decoding="async" width="1024" height="194" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07060647/AMZN-MAY-7-2025-1024x194.jpg" alt="" class="wp-image-905243" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07060647/AMZN-MAY-7-2025-1024x194.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07060647/AMZN-MAY-7-2025-300x57.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07060647/AMZN-MAY-7-2025-768x145.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07060647/AMZN-MAY-7-2025-1536x290.jpg 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07060647/AMZN-MAY-7-2025.jpg 1629w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
AMZN scores well on Growth and Quality metrics and has satisfactory Momentum and Value scores. For more such insights, sign up for<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"> Benzinga Edge</a> today!
Check out more of Benzinga's Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/05/45126638/tesla-will-own-the-autonomous-market-dan-ives-says-shrugging-off-waymo-toyota-agreement">Waymo-Toyota Tie-Up A Threat To Elon Musk&#8217;s Tesla? Dan Ives Dismisses It, Says &#8216;No One Can Compete With Their Scale And Scope&#8217;</a></li>
</ul>

Tech

AMZN

GOOG

GOOGL

TSLA

UBER

VLKAF

Amazon's Tesla Robotaxi Rival Zoox Recalls 270 Driverless Vehicles Following Las Vegas Crash In April: Report

WIIM

AMD shares are trading higher following better-than-expected Q1 financial results.

SEKEY

Epson Has Made A Strategic Investment In Blank Beauty Inc., A Knoxville-based Tech Platform That Enables On-demand, Customized Manufacturing Of Consumer Packaged Goods

ANET

Arista Networks shares are trading lower after the company reported a Q1 sales miss.

Taboola.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBLA#NASDAQ">TBLA</a>) sees Q2 sales of $438.000 million-$458.000 million vs $445.92 million analyst estimate.

TBLA

Taboola.com Sees Q2 Sales $438.000M-$458.000M vs $445.92M Est

MRVL

Marvell shares are trading lower after the company postponed its Investor Day amid uncertainty.

Taboola.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBLA#NASDAQ">TBLA</a>) affirms FY2025 sales outlook from $1.84 billion-$1.89 billion to $1.84 billion-$1.89 billion vs $1.86 billion estimate.

Taboola.com Affirms FY2025 Sales Guidance of $1.84B-$1.89B vs $1.86B Est

WW International shares rae trading lower after the company voluntarily initiated a pre-packaged Chapter 11 bankruptcy filing in Delaware.

Taboola.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBLA#NASDAQ">TBLA</a>) reported quarterly earnings of $0.07 per share which beat the analyst consensus estimate of $0.05 by 40 percent. This is a 600 percent increase over earnings of $0.01 per share from the same period last year. The company reported quarterly sales of $427.49 million which beat the analyst consensus estimate of $418.97 million by 2.04 percent. This is a 3.26 percent increase over sales of $414.01 million the same period last year.

Taboola.com Q1 Adj. EPS $0.07 Beats $0.05 Estimate, Sales $427.49M Beat $418.97M Estimate

RDWR

Radware Is Executing An Aggressive Strategy To Expand Its Market Presence And Accelerate Growth Across Its Cloud Services Business In The U.S

Health Care

Press Releases

NuCana to Present at the Jefferies Global Healthcare Conference

NuCana Reports Second Quarter 2024 Financial Results and Provides Business Update

NuCana Announces Update for Phase 2 Randomized Colorectal Cancer Study

General

NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024

Legal

NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United States

NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel

NuCana Reports Third Quarter 2024 Financial Results and Provides Business Update

Aurion Biotech Appoints Donald Munoz as Chief Financial Officer

NuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update

NuCana Prices $7 Million Registered Direct Offering

NCNA

Aditxt

Apollomics

Aptevo Therapeutics

Bone Biologics

Entero Therapeutics

Genprex

GRI Bio

Lixte Biotechnology Holdings, Inc. - Common Stock

Lixte Biotechnology

Mustang Bio

Matinas Biopharma Holdings, Inc. Common Stock

Matinas BioPharma Hldgs

Onconetix

Psyence Biomedical Ltd. - Ordinary Shares

Psyence Biomedical

Plus Therapeutics

Protagenic Therapeutics, Inc. - Common Stock

Protagenic Therapeutics

Qualigen Therapeutics, Inc. - Common Stock

Qualigen Therapeutics

Revelation Biosciences, Inc. - Common Stock

Revelation Biosciences

Scinai Immunotherapeutics Ltd. - American Depositary Shares

Scinai Immunotherapeutics

Shuttle Pharmaceuticals Holdings, Inc. - common stock

Shuttle Pharmaceuticals

Salarius Pharmaceuticals, Inc. - Common Stock

Salarius Pharmaceuticals

Tharimmune

Windtree Therapeutics, Inc. - Common Stock

Windtree Therapeutics

ZyVersa Therapeutics, Inc. - Common Stock

Comments

NuCana

뉴스

에 대한 최신 뉴스 NuCana (NASDAQ:NCNA) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌